MTOR and Parkinson disease: The mammalian target of rapamycin (mTOR) is a central regulator and modulates multiple aspects of ALP; hence, it is a novel therapeutic target for PD (Bove et al., 2011; Jiang et al., 2013; Xu et al., 2014; Zhu et al., 2019).